Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids

Definitions

• the lower alkyl or alkanoyl groups can contain 1 to 4 carbon atoms.
• R 1 preferably represents methyl, ethyl or hydrogen.
• R 2 preferably represents lower alkyl, in particular alkyl having 1 to 3 carbon atoms, preferably methyl, or hydrogen.
• R 3 preferably represents halogen, in particular fluorine, chlorine or bromine, preferably chlorine.
• the halogen substituent R 4 is in particular chlorine or bromine, preferably bromine.
• 1-Methyl-7-bromo-2-methoxymethyl-5- (2-chlorophenyl) -1H-2,3-dihydro-1,4- is particularly suitable. benzodiazepine and its physiologically acceptable acid addition salts.
• benzodiazepine derivatives of the formula I used as analgesic active ingredients in the pharmaceutical preparations according to the invention fall under 5-phenyl-1H-2,3-dihydro-1,4-benzodiazepine compounds which carry a substituted methyl radical in the 2-position and which are known from the German published documents 22 21 558, 23 55 160, 25 20 937 and 31 38 769 as well as Belgian patent 799 001 and European patent application 82 108 758 are known and which have central nervous system influencing, in particular anxiolytic and tranquilizing properties.
• the object of the invention is to develop new analgesically active pharmaceutical preparations with an improved activity profile.
• the compounds of the formula I are notable for a novel activity profile and, in addition to the aforementioned CNS effects, also have a strong analgesic action component.
• the analgesic effect of the substances of the Formula I surprisingly develops in a dose range in which sedating and muscle-relaxing effects cannot yet be observed.
• the compounds of the formula I prove to be particularly suitable as valuable active substances for the treatment of pain and for the production of pain-relieving pharmaceutical preparations.
• analgesic activity and the good tolerance of the compounds of formula I in particular the favorable ratio of analgesically effective doses to doses in which undesirable sedative and muscle relaxant properties can be observed, can be demonstrated in standard pharmacological tests on animals, e.g. by comparing the pain-inhibiting effects in the arthritis pain test and the sedative and muscle-relaxing effects in rats affecting general activity.
• mice of the OFA strain with a weight of 160-180 g are anesthetized by administration of 20 mg / kg ip pentobarbital sodium.
• 0.1 ml of a suspension of Mycobacterium Smegmae (SI043) in paraffin oil (0.6 mg Mycobakt./0.1 ml oil) is injected intracutaneously into the left hind paw. 14 days later, when a pronounced secondary arthritis has developed especially in the right hind paw, the effects of the test substances are examined. 30 minutes before administration When the test substances are reached, a control measurement is made by bending the ankle of the right hind paw three times and counting the number of sounds. Rats that do not react are discarded. The diffraction procedure is repeated 3 hours after oral administration of the test substances. Animals that sound only once or not at all are considered to be protected against pain. ED 50 is the dose that provides protection in 50% of the animals treated.
• test substance is administered orally to male rats of the Spraque-Dawley type in the form of a suspension in 2% tylose solution 1 hour before the start of the experiment. 6 pairs of rats are used per dose. The rats are placed in pairs in an environment unknown to them and their locomotor activity in the exploration and curiosity phase during the first 30 seconds is registered by 2 observers. The activity is rated according to a point system, with the highest possible score for 6 pairs being 18 points. The ED 50 is the dose that gives 9 points for the 6 pairs.
• the following table shows the test methods for 1-methyl-7-bromo-2-methoxymethyl-5- (2-chlorophenyl) -1H-2,3-dihydro-1,4-benzodiazepine (compound no. 1, as hydrochloride) and for 1-methyl-7-chloro-2-methoxymethyl-5- (2-chlorophenyl) -1H-2,3-dihydro-1,4-benzodiazepine (compound No. 2, obtained as hydrochloride) with the values obtained for the comparison substance diazepam (7-chloro-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one).
• the compounds of the formula I can be used in the form of the free bases or their physiologically tolerable acid addition salts as active ingredients for the treatment of pain and for the preparation of analgesically active pharmaceutical preparations.
• Suitable physiologically acceptable acid addition salts of the compounds of the formula I are, for example, their salts with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid, or salts with organic acids such as maleic acid, fumaric acid, acetic acid, benzoic acid, methanesulfonic acid, cyclohexylaminosulfonic acid, lactic acid or tartaric acid, tartaric acid .
• the doses to be used can vary individually and naturally vary depending on the type of condition to be treated, the substance used and the form of administration.
• parenteral formulations will generally contain less active ingredient than oral preparations.
• pharmaceutical forms with an active ingredient content of 0.25 to 25, in particular 5 to 15 mg of active ingredient per single dose are suitable for application to humans and larger mammals.
• the compounds of the formula I can be present in solid or liquid pharmaceutical preparations together with customary pharmaceutical auxiliaries and / or carriers.
• solid preparations are orally administrable preparations such as tablets, capsules, powders, granules or dragees or suppositories.
• Solid preparations can be pharmaceutically customary inorganic and / or organic carriers such as e.g. Talc, milk sugar or starch in addition to pharmaceutically customary auxiliaries, for example lubricants such as magnesium stearate or tablet disintegrants.
• Liquid preparations such as solutions, suspensions or emulsions can contain the usual diluents such as water, oils or petroleum jelly and / or suspending agents such as polyoxyethylene glycol and the like. Additional auxiliary substances can also be added, e.g. Preservatives, stabilizers, flavor correctors and the like.
• solid oral dosage forms can also delay the release of the active substance, e.g. Contain polyvinyl acetates, acrylate or methacrylate copolymers, higher fatty alcohols and other waxy substances.
• the active ingredients can be mixed and formulated with the pharmaceutical auxiliaries and / or carriers in a manner known per se.
• the active ingredients can be mixed, for example, with the auxiliaries and / or carriers in the customary manner and granulated wet or dry. J e on the type of the additives used a directly compressible powder may optionally also be obtained by simple mixing.
• the granules or powder can be filled directly into capsules or pressed into tablet cores in the usual way. If desired, these can be dragged in a known manner.
• the compounds of formula I are known from DOS 22 21 558, 23 55 160, 25 20 957 and 31 38 769 as well as Belgian patent 799 001 and European patent application 82 108 758 or can be prepared by the processes described in these patents.
• a nucleophilic reagent for example an alkali metal hydroxide or alcoholate
• R 4 ' is hydrogen, this can be converted into chlorine or bromine in a manner known per se in the compounds of the formulas IIIa and IIIb, or, if desired, subsequently in the end products of the formula I, for example by treatment with chloro- or bromosuccinimide .
• Tablets are produced in the following composition per tablet:
• the active ingredient, corn starch and milk sugar are thickened with the 10% gelatin solution.
• the paste is crushed and the resulting granulate is placed on a suitable plate and dried at 45 ° C.
• the dried granulate is passed through a comminution machine and mixed in a mixer with the following auxiliaries:
• the tablet cores produced according to Example 1 are coated in a manner known per se and the coated tablets obtained are polished using beeswax.
• Tablets are produced in the following composition per tablet:
• the ingredients are processed into tablets of 240 mg weight as described in Example 1.
• Capsules are made with the following composition per capsule:
• the sieved substances are mixed and the powder obtained is filled into capsules in 200 mg portions.
• Suppositories are produced in the following composition per suppository:
• the active ingredient and the finely grated suppository base are mixed thoroughly and then melted. Suppositories of 2 g are poured from the melt, which is kept homogeneous by stirring.
• the active ingredient is dissolved in dimethylacetamide and mixed with benzyl alcohol, propylene glycol, ethanol and water. It is filtered through a candle filter, filled into suitable ampoules, sealed and sterilized.
• a drip solution with the following composition per ml is prepared:
• the active ingredient is dissolved in the liquid components and the solution is poured into dropper bottles.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Pain & Pain Management (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)

Priority Applications (1)

Applications Claiming Priority (2)

Publications (2)

Family

ID=6165505

Family Applications (1)

Country Status (9)

Cited By (1)

Families Citing this family (2)

Citations (3)

Family Cites Families (1)

• 1982
  • 1982-06-05 DE DE19823221402 patent/DE3221402A1/de not_active Withdrawn
• 1983
  • 1983-04-27 IT IT20808/83A patent/IT1175915B/it active
  • 1983-05-02 BE BE0/210677A patent/BE896635A/fr unknown
  • 1983-05-16 US US06/494,645 patent/US4482548A/en not_active Expired - Fee Related
  • 1983-05-28 EP EP83105297A patent/EP0096320B1/fr not_active Expired
  • 1983-05-28 DE DE8383105297T patent/DE3363261D1/de not_active Expired
  • 1983-05-28 AT AT83105297T patent/ATE19472T1/de not_active IP Right Cessation
  • 1983-06-02 JP JP58097035A patent/JPS58219119A/ja active Pending
  • 1983-06-03 PH PH29012A patent/PH21768A/en unknown
  • 1983-06-03 AU AU15416/83A patent/AU567498B2/en not_active Ceased

Patent Citations (3)

Also Published As

Similar Documents

Legal Events